2nd Quarter - Report

CVS HEALTH (AND SUBSIDIARIES) for CVS HEALTH (AND SUBSIDIARIES)

Firm
Client
Income
—
Expenses
$1,300,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Issues related to veterans access to healthcare and VA CHOICE Act reauthorization. S. 2372, The VA MISSION Act

LobbyistCovered position, as disclosed
SHANNON PENBERTHY —
AMY ROSENBAUM —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 2372 (115th)

Labor Issues/Antitrust/Workplace LBR

Issues related to CVS Health announced merger with Aetna.

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ASHLI PALMER —
SHANNON PENBERTHY —
AMY ROSENBAUM —
MELISSA SCHULMAN —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Issues related to health savings accounts, the health insurance tax and other taxes included in the Affordable Care Act. H.R. 5138, The Bipartisan HSA Improvement Act of 2018 H.R. 5963, To delay the reimposition of the annual fee on health insurance providers until after 2020

LobbyistCovered position, as disclosed
TEGAN GELFAND —
SHANNON PENBERTHY —

Contacted: SENATE; White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5138 (115th), H.R. 5963 (115th)

Copyright/Patent/Trademark CPT

Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS. S. 124, The Preserve Access to Affordable Generics Act of 2017 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ASHLI PALMER —
SHANNON PENBERTHY —
AMY ROSENBAUM —
MELISSA SCHULMAN —

Contacted: SENATE; White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2212 (115th), S. 771 (115th), S. 974 (115th), S. 124 (115th), H.R. 1776 (115th), H.R. 2051 (115th)

Health Issues HCR

Issues related to implementation and changes to the Affordable Care Act.

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ASHLI PALMER —
SHANNON PENBERTHY —
AMY ROSENBAUM —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Issues related to prescription drug abuse and Medicare Part D. S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2017 H.R.1316, The Prescription Drug Price Transparency Act of 2017 S. 2460/H.R. 3528, The Every Prescription Conveyed Securely Act of 2017 S. 2553/H.R. 6144, The Know the Lowest Price Act of 2018 H.R. 4841, The Standardizing Electronic Prior Authorization for Safe Prescribing Act H.R. 5958, The Phair Pricing Act of 2018

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ASHLI PALMER —
SHANNON PENBERTHY —
AMY ROSENBAUM —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1039 (115th), H.R. 6144 (115th), H.R. 1316 (115th), S. 413 (115th), H.R. 4841 (115th), H.R. 3528 (115th), S. 2460 (115th), S. 2553 (115th), H.R. 5958 (115th)

Pharmacy PHA

Issues related to prescription drug abuse, medication adherence, drug price transparency, and gag clauses. H.R. 1316, The Prescription Drug Price Transparency Act of 2017 S. 778/H.R. 1854, The Prescription Drug Monitoring Act of 2017 S. 2460/H.R. 3528, The Every Prescription Conveyed Securely Act of 2017 S. 892/H.R. 4408, The Opioid Addiction Prevention Act of 2017 S. 2456/H.R. 5311, The CARA 2.0 Act of 2018 S. 2553/H.R. 6144, The Know the Lowest Price Act of 2018 S. 2554/H.R. 6143, The Patient Right to Know Drug Prices Act of 2018 H.R. 5343, The Prescription Transparency Act of 2018 H.R. 6, The SUPPORT for Patients and Communities Act of 2018 H.R. 6133, The Informing Opioid Prescribing Through Evidence-Based Guidelines Act of 2018

LobbyistCovered position, as disclosed
ELIZABETH BROOKS —
TEGAN GELFAND —
ASHLI PALMER —
SHANNON PENBERTHY —
AMY ROSENBAUM —
MELISSA SCHULMAN —

Contacted: White House Office; SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 2456 (115th), H.R. 6143 (115th), S. 2554 (115th), S. 2460 (115th), S. 2553 (115th), H.R. 5343 (115th), H.R. 5311 (115th), S. 892 (115th), H.R. 6133 (115th), S. 778 (115th), H.R. 6144 (115th), H.R. 3528 (115th), H.R. 6 (115th), H.R. 1854 (115th), H.R. 4408 (115th), H.R. 1316 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.